Article

Sugar Crash on the PI3K Pathway: The First Report of Inavolisib-Associated Diabetic Ketoacidosis

2026-06-23

Abstract excerpt

Phosphatidylinositol-3-kinase (PI3K) inhibitors are an important targeted therapy for advanced, PIK3CA-mutated breast cancer, and hyperglycemia is a common adverse effect. However, diabetic ketoacidosis (DKA) is rare and has not previously been reported with the next-generation PI3K inhibitor inavolisib. We describe a 76-year-old woman with metastatic hormone receptor-positive, HER2-negative breast cancer and prev...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4292b2fd-63a3-5087-851c-f3c2a971a9f0
DOI: 10.20944/preprints202606.1708.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sugar Crash on the PI3K Pathway: The First Report of Inavolisib-Associated Diabetic KetoacidosisDOI 10.20944/preprints202606.1708.v1Read

Sugar Crash on the PI3K Pathway: The First Documented Case of Inavolisib-Associated Diabetic KetoacidosisSemantic proximity Read

Paradoxical Diabetic Ketoacidosis in a Type 2 Diabetes patient on Dapagliflozin: A Brief Case ReportSemantic proximity Read

Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.Semantic proximity Read

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.Semantic proximity Read

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancerSemantic proximity Read

Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.Semantic proximity Read

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity Read

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.Semantic proximity Read

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read

Itaconate delays type 2 diabetes progression by alkylating RIPK3 to inhibit pancreatic β‑cell failureSemantic proximity Read

Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability.Semantic proximity Read